- Home
- AARD vs ELDN Comparison
AARD vs ELDN Comparison
Compare AARD & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- ELDN
- Stock Information
- Founded
- AARD 2017
- ELDN 2004
- Country
- AARD United States
- ELDN United States
- Employees
- AARD N/A
- ELDN N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- AARD Health Care
- ELDN Health Care
- Exchange
- AARD Nasdaq
- ELDN Nasdaq
- Market Cap
- AARD 154.9M
- ELDN 178.4M
- IPO Year
- AARD 2025
- ELDN N/A
- Fundamental
- Price
- AARD $13.68
- ELDN $3.67
- Analyst Decision
- AARD Strong Buy
- ELDN Strong Buy
- Analyst Count
- AARD 5
- ELDN 2
- Target Price
- AARD $33.00
- ELDN $12.50
- AVG Volume (30 Days)
- AARD 84.2K
- ELDN 849.2K
- Earning Date
- AARD 08-14-2025
- ELDN 08-18-2025
- Dividend Yield
- AARD N/A
- ELDN N/A
- EPS Growth
- AARD N/A
- ELDN N/A
- EPS
- AARD N/A
- ELDN N/A
- Revenue
- AARD N/A
- ELDN N/A
- Revenue This Year
- AARD N/A
- ELDN N/A
- Revenue Next Year
- AARD N/A
- ELDN N/A
- P/E Ratio
- AARD N/A
- ELDN N/A
- Revenue Growth
- AARD N/A
- ELDN N/A
- 52 Week Low
- AARD $4.88
- ELDN $2.38
- 52 Week High
- AARD $19.58
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- ELDN 67.56
- Support Level
- AARD N/A
- ELDN $3.64
- Resistance Level
- AARD N/A
- ELDN $3.93
- Average True Range (ATR)
- AARD 0.00
- ELDN 0.23
- MACD
- AARD 0.00
- ELDN 0.05
- Stochastic Oscillator
- AARD 0.00
- ELDN 71.91
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.